{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T11:26:19Z","timestamp":1772191579178,"version":"3.50.1"},"reference-count":10,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.eimc.2020.04.005","type":"journal-article","created":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T17:56:49Z","timestamp":1589824609000},"page":"108-109","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Leishmaniasis cut\u00e1nea facial tratada con imiquimod al 3,75%"],"prefix":"10.1016","volume":"39","author":[{"given":"Ignasi","family":"Marti-Marti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merc\u00e8","family":"Alsina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priscila","family":"Giavedoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Fuertes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eimc.2020.04.005_bib0055","doi-asserted-by":"crossref","first-page":"24","DOI":"10.4269\/ajtmh.16-84256","article-title":"Diagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH)","volume":"96","author":"Aronson","year":"2017","journal-title":"Am J Trop Med Hyg."},{"key":"10.1016\/j.eimc.2020.04.005_bib0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2018\/9014726","article-title":"Pentavalent Antimonials Combined with Other Therapeutic Alternatives for the Treatment of Cutaneous and Mucocutaneous Leishmaniasis: A Systematic Review","volume":"2018","author":"Berbert","year":"2018","journal-title":"Dermatol Res Pract."},{"key":"10.1016\/j.eimc.2020.04.005_bib0065","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1046\/j.1365-4362.2003.01955.x","article-title":"Transient effect of topical treatment of cutaneous leishmaniasis with imiquimod","volume":"42","author":"Seeberger","year":"2003","journal-title":"Int J Dermatol."},{"key":"10.1016\/j.eimc.2020.04.005_bib0070","doi-asserted-by":"crossref","first-page":"P118","DOI":"10.1016\/j.jaad.2004.10.481","article-title":"Comparative study of the efficacy of combined imiquimod 5% cream and intralesional meglumine antimoniate versus imiquimod 5% cream and intralesional meglumine antimoniate alone for the treatment of cutaneous leishmaniasis","volume":"52","author":"Crawford","year":"2005","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.eimc.2020.04.005_bib0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000491","article-title":"First-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimony","author":"Miranda-Verastegui","year":"2009","journal-title":"PLoS Negl Trop Dis."},{"key":"10.1016\/j.eimc.2020.04.005_bib0080","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1086\/518172","article-title":"Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous leishmaniasis","volume":"44","author":"Arevalo","year":"2007","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.eimc.2020.04.005_bib0085","first-page":"238","article-title":"Comparative histological and immunohistochemical changes of dry type cutaneous leishmaniasis after administration of meglumine antimoniate, imiquimod or combination therapy","volume":"14","author":"Shamsi Meymandi","year":"2011","journal-title":"Arch Iran Med."},{"key":"10.1016\/j.eimc.2020.04.005_bib0090","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1086\/429238","article-title":"Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru","volume":"40","author":"Miranda-Ver\u00e1stegui","year":"2005","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.eimc.2020.04.005_bib0095","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1001\/archderm.142.12.1575","article-title":"Imiquimod in combination with meglumine antimoniate for cutaneous leishmaniasis: a randomized assessor-blind controlled trial","volume":"142","author":"Firooz","year":"2006","journal-title":"Arch Dermatol."},{"key":"10.1016\/j.eimc.2020.04.005_bib0100","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/INF.0b013e31822dfbf7","article-title":"Old world Leishmania infantum cutaneous leishmaniasis unresponsive to liposomal amphotericin B treated with topical imiquimod","volume":"31","author":"Herv\u00e1s","year":"2012","journal-title":"Pediatr Infect Dis J."}],"container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X20301828?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X20301828?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T13:05:53Z","timestamp":1759323953000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0213005X20301828"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S0213005X20301828"],"URL":"https:\/\/doi.org\/10.1016\/j.eimc.2020.04.005","relation":{},"ISSN":["0213-005X"],"issn-type":[{"value":"0213-005X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Leishmaniasis cut\u00e1nea facial tratada con imiquimod al 3,75%","name":"articletitle","label":"Article Title"},{"value":"Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eimc.2020.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.","name":"copyright","label":"Copyright"}]}}